<DOC>
	<DOCNO>NCT02537015</DOCNO>
	<brief_summary>This study evaluate long-term ( 9-months ) safety Bimatoprost Ocular Insert subject Glaucoma Ocular Hypertension . All subject receive Bimatoprost Ocular Insert wear approximately 3 month ( 12 week ) , Insert remove new Insert place another 24 week ( approximately 6 month ) .</brief_summary>
	<brief_title>An Open-label Extension Study Evaluate Safety 13 mg Bimatoprost Ocular Insert</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<criteria>1 . Completed FSV5004 study . 2 . Written inform consent prior study procedure . 3 . Willingness comply visit schedule . Key 1 . Participation investigational drug device study FSV5004 within past 6 month anticipate participation study period . 2 . Subjects require contact lens use study period . 3 . Any condition situation ( uncontrolled systemic disease ) , Investigator 's opinion , might confound result study , may put subject significant risk might interfere subject 's ability participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>